Evidence map›Paper›PMID 26380232›Full record

ArticleThe journal of prevention of Alzheimer's disease

Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction.

Kaarin J Anstey, Ranmalee Eramudugolla, Diane E Hosking, Nicola T Lautenschlager, Roger A Dixon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. What We Learn from the CTAD (Clinical Trials Alzheimer's Disease) 2018.The journal of prevention of Alzheimer's disease · 2018
    Article
  14. The future of dementia risk reduction research: barriers and solutions.Journal of public health (Oxford, England) · 2017
    Article
  15. Article
  16. Memory Resilience to Alzheimer's Genetic Risk: Sex Effects in Predictor Profiles.The journals of gerontology. Series B, Psychological sciences and social sciences · 2017
    Article
  17. Article
  18. Insight into the Molecular Imaging of Alzheimer's Disease.International journal of biomedical imaging · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaarin J AnsteyCentre for Research on Ageing, Health and Wellbeing, Research School of Population Health, Australian National University.
Ranmalee EramudugollaCentre for Research on Ageing, Health and Wellbeing, Research School of Population Health, Australian National University.
Diane E HoskingCentre for Research on Ageing, Health and Wellbeing, Research School of Population Health, Australian National University.
Nicola T LautenschlagerAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne ; School of Psychiatry and Clinical Neurosciences & WA Centre for Health and Ageing, University of Western Australia.
Roger A DixonDepartment of Psychology, University of Alberta, Canada.

Funding

LONGITUDINAL STUDY OF COGNITIVE AGINGR01AG008235 · NIA · UNIVERSITY OF VICTORIA · PI DIXON, ROGER A · 1989 to 2017
$2.3M
NIA NIH HHS R01 AG008235
6 · The paper itself

Abstract

Dementia risk reduction is a global health and fiscal priority given the current lack of effective treatments and the projected increased number of dementia cases due to population ageing. There are often gaps among academic research, clinical practice, and public policy. We present information on the evidence for dementia risk reduction and evaluate the progress required to formulate this evidence into clinical practice guidelines. This narrative review provides capsule summaries of current evidence for 25 risk and protective factors associated with AD and dementia according to domains including biomarkers, demographic, lifestyle, medical, and environment. We identify the factors for which evidence is strong and thereby especially useful for risk assessment with the goal of personalising recommendations for risk reduction. We also note gaps in knowledge, and discuss how the field may progress towards clinical practice guidelines for dementia risk reduction.

Indexed as

Alzheimer diseasecognitive declinepreventionrisk assessmentRisk factor

Identifiers

PMID26380232
PMCPMC4568745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.